1. Home
  2. YI vs VNRX Comparison

YI vs VNRX Comparison

Compare YI & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 111 Inc.

YI

111 Inc.

HOLD

Current Price

$3.60

Market Cap

38.1M

ML Signal

HOLD

Logo VolitionRX Limited

VNRX

VolitionRX Limited

HOLD

Current Price

$0.24

Market Cap

38.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YI
VNRX
Founded
2010
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.1M
38.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
YI
VNRX
Price
$3.60
$0.24
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.17
AVG Volume (30 Days)
13.5K
2.8M
Earning Date
12-05-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,979,883,442.00
$1,472,007.00
Revenue This Year
N/A
$55.33
Revenue Next Year
N/A
$493.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.48
52 Week Low
$3.19
$0.27
52 Week High
$11.35
$0.94

Technical Indicators

Market Signals
Indicator
YI
VNRX
Relative Strength Index (RSI) 35.89 27.78
Support Level $3.32 $0.28
Resistance Level $3.94 $0.31
Average True Range (ATR) 0.21 0.03
MACD 0.00 0.00
Stochastic Oscillator 14.46 8.26

Price Performance

Historical Comparison
YI
VNRX

About YI 111 Inc.

111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Share on Social Networks: